Comparative Pharmacology
Head-to-head clinical analysis: NORQUEST FE versus OVRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORQUEST FE versus OVRAL.
NORQUEST FE vs OVRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NORQUEST FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Norethindrone induces progestational changes in the endometrium, increasing cervical mucus viscosity, and also inhibits ovulation.
OVRAL is a combination oral contraceptive containing ethinyl estradiol and norgestrel. It inhibits ovulation by suppressing gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus, reducing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) release from the pituitary. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.
One tablet orally once daily, each tablet containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol (21 active tablets) followed by 7 ferrous fumarate tablets.
One tablet (norgestrel 0.3 mg with ethinyl estradiol 0.03 mg) orally once daily for 21 days followed by 7 days of placebo.
None Documented
None Documented
Terminal half-life: 6-8 hours. Clinical context: Supports once-daily dosing with sustained therapeutic effect.
Norgestrel: 24–32 hours; Ethinyl estradiol: 12–18 hours; steady-state achieved after 5–7 days
Renal: 80% (50% unchanged, 30% as metabolites); Fecal: 19%; Biliary: <1%
Renal (60% as metabolites, ~40% unchanged); biliary/fecal (40%)
Category C
Category C
Oral Contraceptive
Oral Contraceptive